CN104984268A - Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN104984268A CN104984268A CN201510481888.XA CN201510481888A CN104984268A CN 104984268 A CN104984268 A CN 104984268A CN 201510481888 A CN201510481888 A CN 201510481888A CN 104984268 A CN104984268 A CN 104984268A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention belongs to the technical field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition treating cerebral thrombosis and a preparing method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from horseradish tree leaves, pseudo-ginseng, the root of red-rooted salvia, ligusticum wallichii, rhizoma sparganii, curcuma aromatica, selfheal, caulis spatholobi, uncaria, fructus viticis, lucid ganoderma, polygonum multiflorum, rhizoma arisaematis, scorpio and liquorice. The traditional Chinese medicine composition has the effects of promoting blood circulation to remove meridian obstruction, dissipating stasis, relieving pain, reinforcing qi, nourishing blood and the like. Meanwhile, the traditional Chinese medicine composition has the effects of reducing the blood glucose, the blood fat and the blood pressure and is obvious in effect on preventing and treating the cerebral thrombosis.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the treatment of cerebral thrombosis and preparation method thereof.
Background technology
Acute cerebrovascular disease is the disease of the hurried cerebral vessels circulatory disturbance of one group of onset, and be neural commonly encountered diseases and frequently-occurring disease, disability rate and fatality rate are all higher.Cerebral thrombosis is one of three large common acute cerebrovascular, Basic disease cause causes Aldosterone, luminal stenosis obturation due to self pathological changes such as atherosclerosiss or on narrow basis, forms thrombosis, cause brain regional blood flow to reduce or blood supply interruption, brain tissue ischemia anoxia causes the focal neurological symptom of softening downright bad appearance.The common site of cerebral thrombosis is internal carotid artery, middle cerebral artery, vertebral artery and basilar artery, thus causes the position of these tremulous pulse blood supplies to form infringement due to hypoxic-ischemic.Clinical main manifestations is occur that suddenly inclined side upper and lower extremities numbness is unable, facial hemiparalysis, slurred speech etc., along with advancing of disease, time serious, the complication such as pulmonary infection, cerebrocardiac syndrome, injury of hypothalamus, syndrome of inapropriate ADH and multiple organ failure, MOF can be produced.
Western medical treatment cerebral thrombosis, to improve the blood circulation of Cerebral Region, promotion neurological functional recovery as early as possible for principle, conventional Therapeutic Method has Hemodilution Therapy, thrombolytic therapy and anticoagulant therapy.Thrombolytic therapy is applicable to the extreme early of cerebral thrombosis, needs to treat in 3 ~ 6 hours in morbidity, treats in time, Be very effective within this time period, but exceedes this time period and apply thrombolytic therapy again, and effect is very low.Hemodilution Therapy and anticoagulant therapy are carried out mainly through intravenous drip relative medicine, and Therapeutic Method is inconvenient.Western medicine therapy side effect is obvious, expensive, and the treatment later stage also needs prolonged administration of drugs maintaining treatment effect, prevention of recurrence.
Cerebral thrombosis belongs to TCM Stroke category, is referred to as ancient times such as apoplexy, coma, hemiplegia, hemiplegia, apoplexy etc.According to the dialectical principle treated, cerebral thrombosis can be divided into again the cards such as the resistance of wind sun network, obstruction of collateral caused by windphlegm, phlegm-heat accumulation, blood stasis due to qi deficiency, deficiency of kidney essence.Cow-bezoar bolus for resurrection and restorative bolus are the more common medicines of current Chinese traditional treatment apoplexy, have certain curative effect, but price are very expensive for treatment cerebral thrombosis.
Chinese patent application 201410113186.1 discloses a kind of Chinese medicine composition for the treatment of cerebral thrombosis and preparation method thereof, it obtains primarily of following raw material: Semen Persicae 10-50 part, Rhizoma Et Radix Notopterygii 10-20 part, Flos Sophorae 5-20 part, Radix Cynanchi Paniculati 5-15 part, Radix Rehmanniae Preparata 5-10 part, Bulbus Lilii 5-15 part, Flos Lonicerae 5-15 part, Radix Salviae Miltiorrhizae 1-10 part, Fructus Lycii 5-15 part, Poria 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, berberine 0.2-9 part, Radix Paeoniae Alba 5.5-15 part, Radix Rhodiolae 6-9 part, Radix Glycyrrhizae 10-15 part.This Chinese medicine composition has the function of blood circulation promoting and blood stasis dispelling, anti-inflammatory and antalgic, but it is at reduction blood glucose, blood fat and blood pressure, and the function of the aspects such as prevention cerebral thrombosis is not remarkable.
Chinese traditional treatment cerebral thrombosis, has low drug side effect, the features such as treating both the principal and secondary aspects of a disease, has a extensive future, and seeks a kind of rapid-action, good effect, efficacy stability, and cost medicine that is low and that be easy to the treatment cerebral thrombosis promoted the use of is this area urgent problem.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of cerebral thrombosis, this Chinese medicine composition has promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain, benefiting QI and nourishing blood and reduce effect of blood glucose, blood fat and blood pressure, possess therapeutic effect significantly, efficacy stability, treating both the principal and secondary aspects of a disease, applied widely and be easy to advantages such as applying.In addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use finished product preparation under the prerequisite ensureing curative effect by this Chinese medicine.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight:
Leaf of Moringa 28-36 part, Radix Notoginseng 23-28 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Chuanxiong 13-18 part, Rhizoma Sparganii 13-17 part, Radix Curcumae 12-17 part, Spica Prunellae 15-20 part, Caulis Spatholobi 15-19 part, Ramulus Uncariae Cum Uncis 8-12 part, Fructus Viticis 6-14 part, Ganoderma 7-11 part, Radix Polygoni Multiflori 5-8 part, Rhizoma Arisaematis 3-7 part, Scorpio 3-9 part and Radix Glycyrrhizae 5-13 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Leaf of Moringa 34 parts, Radix Notoginseng 26 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Chuanxiong 15 parts, Rhizoma Sparganii 16 parts, Radix Curcumae 15 parts, Spica Prunellae 18 parts, Caulis Spatholobi 18 parts, Ramulus Uncariae Cum Uncis 10 parts, Fructus Viticis 12 parts, Ganoderma 9 parts, Radix Polygoni Multiflori 7 parts, Rhizoma Arisaematis 5 parts, Scorpio 6 parts and 9 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Leaf of Moringa 28 parts, Radix Notoginseng 23 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 13 parts, Rhizoma Sparganii 13 parts, Radix Curcumae 12 parts, Spica Prunellae 15 parts, Caulis Spatholobi 15 parts, Ramulus Uncariae Cum Uncis 8 parts, Fructus Viticis 6 parts, Ganoderma 7 parts, Radix Polygoni Multiflori 5 parts, Rhizoma Arisaematis 3 parts, Scorpio 3 parts and 5 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Leaf of Moringa 36 parts, Radix Notoginseng 28 parts, Radix Salviae Miltiorrhizae 25 parts, Rhizoma Chuanxiong 18 parts, Rhizoma Sparganii 17 parts, Radix Curcumae 17 parts, Spica Prunellae 20 parts, Caulis Spatholobi 19 parts, Ramulus Uncariae Cum Uncis 12 parts, Fructus Viticis 14 parts, Ganoderma 11 parts, Radix Polygoni Multiflori 8 parts, Rhizoma Arisaematis 7 parts, Scorpio 9 parts and 13 parts, Radix Glycyrrhizae.
Present invention also offers the preparation method of described Chinese medicine composition, mainly comprise the following steps:
(1) moringa oleifera leaf extractive is prepared: get dry leaf of Moringa, 200 ~ 270 mesh sieves are crossed after pulverizing, doubly add according to the 12-15 of leaf of Moringa fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 60%-80%, reflux, extract, 2-3 time, each return time is 2-3h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, spraying dry, cross 80-100 mesh sieve, obtain moringa oleifera leaf extractive;
(2) get Radix Salviae Miltiorrhizae, Rhizoma Sparganii, Radix Curcumae, Spica Prunellae, Caulis Spatholobi, Fructus Viticis, Radix Polygoni Multiflori, Scorpio, Rhizoma Arisaematis and Radix Glycyrrhizae, pulverize, add the soak by water 3-4h of medical material gross weight 6-8 times amount, filter; Filtering residue adds the soak by water 2.5-2h of medical material gross weight 4-6 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve, obtain extractum fine powder after pulverizing;
(3) get Radix Notoginseng, Rhizoma Chuanxiong, Ramulus Uncariae Cum Uncis and Ganoderma, grinding, cross 80-100 mesh sieve, fully mix with above-mentioned moringa oleifera leaf extractive, extractum fine powder, obtain this Chinese medicine composition.
Utilize modern general Chinese medicine preparation technology, Chinese medicine composition of the present invention can be made into the finished product preparation of clinical needs, as dosage forms such as granule, pill, powder, tablet or capsules.
Source, the nature and flavor of Chinese medicine composition of the present invention Chinese crude drug used, return through and effect:
Leaf of Moringa: this product is the dried leaves of Moringaceae plant Moringa.Bitter in the mouth, slightly warm in nature; Leaf of Moringa has the effects such as blood sugar lowering, blood fat reducing, blood pressure lowering, antitumor, antioxidation and enhancing immunity.
Radix Notoginseng: this product is the dry root of panax araliaceae plant.Sweet in the mouth, micro-hardship, warm in nature; Return liver, stomach warp; Dissipating blood stasis stops blooding, subduing swelling and relieving pain.
Radix Salviae Miltiorrhizae: this product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae.Bitter in the mouth, cold nature; GUIXIN, Liver Channel; Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.
Rhizoma Chuanxiong: this product is the dry rhizome of samphire Rhizoma Chuanxiong.Acrid in the mouth, warm in nature; Return liver, gallbladder, pericardium channel; Blood-activating and qi-promoting, wind-expelling pain-stopping.
Rhizoma Sparganii: this product is the dry tuber of Sparganiaceae plant rhizoma scirpi.Acrid in the mouth, hardship, property is put down; Return liver, spleen channel; Removing blood stasis circulation of qi promoting, removing food stagnancy pain relieving.
Caulis Spatholobi: this product is the dry rattan of leguminous plant spatholobus suberectus (Caulis Sargentodoxae, Radix seu Caulis Verntilaginis Leiocarpae, SANYE Caulis Spatholobi, nine layers of wind).Bitter in the mouth, sweet, warm in nature; Return liver, kidney channel; Enrich blood, invigorate blood circulation, dredging collateral.
Spica Prunellae: this product is the dry fruit ear of labiate Spica Prunellae.Acrid in the mouth, hardship, cold in nature; Return liver, gallbladder meridian; Relieve inflammation or internal heat, improving eyesight, eliminating stagnation, detumescence.
Radix Curcumae: this product is the dried root of zingiberaceous plant RADIX CURCUMAE, Rhizoma Curcumae Longae, Guangxi zedoary or Rhizoma Curcumae.Acrid in the mouth, hardship, cold in nature; Return liver, the heart, lung meridian; Promoting QI circulation for relieving depression, removing heat from blood removing blood stasis with potent drugs, promoting the function of the gallbladder to alleviate jaundice.
Ramulus Uncariae Cum Uncis: this product is the dry stem and branch with belt hook of Maguireothamnus speciosus Ramulus Uncariae Cum Uncis, Ramulus Uncariae macrophyllae, Ramulus Uncariae Cum Uncis, Uncaria sinensis (Oliv.) Havil. or stockless fruit Ramulus Uncariae Cum Uncis.Sweet in the mouth, cool in nature; Return liver, pericardium channel; Heat clearing away suppressing the hyperactive liver, dispelling wind and relieving convulsion.
Fructus Viticis: this product is the dry mature fruit of Verbenaceae Vitex rotundifolia or wild pepper.Acrid in the mouth, hardship, cold nature; Return bladder, liver, stomach warp; Dispelling wind and heat pathogens, the clear sharp head.
Ganoderma: this product is the dry sporophore of On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. or Ganoderma.Sweet in the mouth, property is put down; GUIXIN, lung, liver, kidney channel; Replenishing QI and blood, tranquilizing mind, strengthening the spleen and stomach.
Radix Polygoni Multiflori: this product is the dried root of polygonum multiflorum thunb.Bitter in the mouth, sweet, puckery, warm in nature; Return liver, the heart, kidney channel; Tonifying liver, kidney tonifying, nourishes blood, and dispels the wind.
Rhizoma Arisaematis: this product is the dry tuber of aroid Rhizoma Arisaematis, Arisaema heterophyllum B1. or arisaema amurense Maxim.Bitter in the mouth, pungent, warm in nature; Return lung, liver, spleen channel; Drying dampness to eliminate phlegm, expellings wind and relieving convulsion, mass dissipating and swelling eliminating.
Scorpio: this product is the dry body of Buthidae animal Scorpio.Acrid in the mouth, property is put down; Return Liver Channel; Endogenous wind stopping spasmolytic, dispersing pathogen accumulation, removing obstruction in the collateral to relieve pain.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of medicament composing prescription of the present invention:
Medicament composing prescription of the present invention with leaf of Moringa, Radix Notoginseng and Radix Salviae Miltiorrhizae for monarch drug, promoting blood circulation to remove blood stasis, subduing swelling and relieving pain, blood sugar lowering, blood fat and blood pressure; With Rhizoma Chuanxiong, Rhizoma Sparganii, Radix Curcumae, Spica Prunellae and Caulis Spatholobi for ministerial drug, blood-activating and qi-promoting, removing food stagnancy pain relieving, resolving mass and removing the obstruction of the collateral, nourishes blood and enriches blood; With Ramulus Uncariae Cum Uncis, Fructus Viticis, Ganoderma, Radix Polygoni Multiflori, Rhizoma Arisaematis and Scorpio for adjuvant drug, the clear sharp head, the liver and the kidney tonifying, nourishing blood and invigorating qi; With Radix Glycyrrhizae for making medicine, invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription, all medicines are arranged in pairs or groups, and synergism, reaches promoting blood circulation to remove obstruction in the collateral jointly, eliminating stasis to stop pain, benefiting QI and nourishing blood, blood fat reducing, effect of blood sugar lowering and blood pressure lowering, has treatment and preventive effect very significantly to cerebral thrombosis.
Compared with prior art, Chinese medicine composition of the present invention has following technical advantage:
(1) compared with positive control drug Xueshuan xinmaining Tablet, Chinese medicine composition Chinese medicine composition of the present invention not only in blood circulation promoting and blood stasis dispelling effect more remarkable, suppressing the rising of LPA and PA, antithrombotic and cerebral ischemia aspect are also significantly better than positive drug, this shows that present composition medicament composing prescription is reasonable, in treatment and prevention cerebral thrombosis, have significant synergism.
(2) Chinese medicine composition of the present invention has rapid-action in treatment cerebral thrombosis, good effects etc. treat advantage significantly, simultaneously, Chinese medicine composition of the present invention can obviously reduce blood glucose, blood fat and blood pressure level, also there is certain inhibitory action to arteriosclerosis and thrombosis, there is the effect of significant prevention cerebral thrombosis.
(3) Chinese medicine composition of the present invention has promoting blood circulation to remove obstruction in the collateral, eliminating stasis to stop pain and benefiting QI and nourishing blood effect, also has efficacy stability simultaneously, rapid-action, toxic and side effects is low and be easy to advantages such as applying.
Detailed description of the invention
Below will further describe the present invention by specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, be included within the scope of the present invention.
embodiment 1
The embodiment of the present invention 1 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Leaf of Moringa 28 parts, Radix Notoginseng 23 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 13 parts, Rhizoma Sparganii 13 parts, Radix Curcumae 12 parts, Spica Prunellae 15 parts, Caulis Spatholobi 15 parts, Ramulus Uncariae Cum Uncis 8 parts, Fructus Viticis 6 parts, Ganoderma 7 parts, Radix Polygoni Multiflori 5 parts, Rhizoma Arisaematis 3 parts, Scorpio 3 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is as follows:
(1) moringa oleifera leaf extractive is prepared: get dry leaf of Moringa, 250 mesh sieves are crossed after pulverizing, add according to 15 times of leaf of Moringa fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 70%, reflux, extract, 2 times, each return time is 3h, merge extractive liquid, reclaim ethanol, be evaporated to the extractum of relative density 1.25 under 60 DEG C of environment, spraying dry, cross 100 mesh sieves, obtain moringa oleifera leaf extractive;
(2) get Radix Salviae Miltiorrhizae, Rhizoma Sparganii, Radix Curcumae, Spica Prunellae, Caulis Spatholobi, Fructus Viticis, Radix Polygoni Multiflori, Scorpio, Rhizoma Arisaematis and Radix Glycyrrhizae, pulverize, add the soak by water 4h of medical material gross weight 7 times amount, filter; Filtering residue adds the soak by water 2.5h of medical material gross weight 5 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60 DEG C of environment is the extractum of 1.25, drying under reduced pressure, crosses 100 mesh sieves, obtain extractum fine powder after pulverizing;
(3) get Radix Notoginseng, Rhizoma Chuanxiong, Ramulus Uncariae Cum Uncis and Ganoderma, grinding, cross 100 mesh sieves, fully mix with above-mentioned moringa oleifera leaf extractive, extractum fine powder, obtain this Chinese medicine composition.
embodiment 2
The embodiment of the present invention 2 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Leaf of Moringa 36 parts, Radix Notoginseng 28 parts, Radix Salviae Miltiorrhizae 25 parts, Rhizoma Chuanxiong 18 parts, Rhizoma Sparganii 17 parts, Radix Curcumae 17 parts, Spica Prunellae 20 parts, Caulis Spatholobi 19 parts, Ramulus Uncariae Cum Uncis 12 parts, Fructus Viticis 14 parts, Ganoderma 11 parts, Radix Polygoni Multiflori 8 parts, Rhizoma Arisaematis 7 parts, Scorpio 9 parts and 13 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3
The embodiment of the present invention 3 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Leaf of Moringa 34 parts, Radix Notoginseng 26 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Chuanxiong 15 parts, Rhizoma Sparganii 16 parts, Radix Curcumae 15 parts, Spica Prunellae 18 parts, Caulis Spatholobi 18 parts, Ramulus Uncariae Cum Uncis 10 parts, Fructus Viticis 12 parts, Ganoderma 9 parts, Radix Polygoni Multiflori 7 parts, Rhizoma Arisaematis 5 parts, Scorpio 6 parts and 9 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 4
The embodiment of the present invention 4 Chinese medicine composition is prepared from primarily of the raw material of following parts by weight:
Leaf of Moringa 30 parts, Radix Notoginseng 26 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Chuanxiong 13 parts, Rhizoma Sparganii 17 parts, Radix Curcumae 16 parts, Spica Prunellae 15 parts, Caulis Spatholobi 16 parts, Ramulus Uncariae Cum Uncis 11 parts, Fructus Viticis 10 parts, Ganoderma 8 parts, Radix Polygoni Multiflori 7 parts, Rhizoma Arisaematis 6 parts, Scorpio 4 parts and 13 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
chinese medicine composition pharmacodynamic study of the present invention:
test one: Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
1, experimental animal: regular grade SD rat 90, body weight 260-320g, male and female half and half, are divided into 9 groups at random, often organize 10.
2, trial drug and dosage regimen:
A group: by Chinese medicine composition obtained for the embodiment of the present invention 1, be deployed into water the suspension that concentration is 0.6g/ml, 0.4g/ml and 0.2g/ml, for subsequent use.Get 3 groups of rats, be labeled as A group high dose group (dosage 2.4g/kg), middle dosage group (dosage 1.6g/kg) and low dose group (dosage 0.8g/kg), high dose group concentration is the drug suspension of 0.6g/ml, middle dosage group concentration is the drug suspension of 0.4g/ml, low dose group concentration is the drug suspension of 0.2g/ml, according to dosage every day gavage 1 time, successive administration 7 days.
B group: trial drug is the Chinese medicine composition that the embodiment of the present invention 2 obtains, and dosage regimen is with A group.
Positive controls: positive control drug is Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), be deployed into the suspension of 0.6g/ml with water, get 1 group of rat, by dosage gastric infusion every day 1 time of 2.4g/kg, successive administration 7 days.
Model control group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Normal group: get 1 group of rat, the same model control group of dosage regimen.
3, the foundation of rat blood stasis models:
After last administration 1h, except Normal group, all the other respectively organize rat skin lower injection adrenalin hydrochloride 10 μ g/kg totally 2 times, interval 4h.Between double injection adrenalin hydrochloride, front and back are respectively every 2h, and rat being immersed water temperature is 5min in the frozen water of 4 DEG C, causes blood stasis model.After modeling, water is can't help in the equal fasting of each group rat, and the next morning anaesthetizes with pentobarbital sodium, heart extracting blood 4ml, shake up standing in the anticoagulant tube that wherein 2ml injects rapidly containing heparin, after measuring whole blood viscosity, by its low-speed centrifugal, isolate blood plasma, measure plasma viscosity and hematocrit (Hct); 2ml injects in the silication pipe containing 3.8% sodium citrate in addition, for detecting erythrocyte sedimentation rate (ESR), finally calculates ESR equation K value.
4, result of the test: as shown in table 1.
Table 1 Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
Continued 1 Chinese medicine composition of the present invention is on the impact of blood stasis model hemorheology of rat
Note: compare with Normal group, model control group
# p> 0.05,
## p> 0.01; Compare with model control group, drug test group
* p< 0.05,
* p< 0.01.
5, conclusion (of pressure testing):
Test data shows, and compare with Normal group, the equal significance of hemorheology index of rat blood stasis models group increases, consistent with the hemorheology feature of blood stasis type disease, can be used for research Chinese medicine composition of the present invention to the therapeutic effect of cerebral thrombosis.
Compare with model control group, Chinese medicine composition A group of the present invention, namely the Chinese medicine composition high dose group that the embodiment of the present invention 1 is obtained and middle dosage group all significantly can improve the hemorheology index of blood stasis model rat, action effect is better than positive controls, and low dose group also can reduce the level of each hemorheology index to a certain extent.
Compare with model control group, Chinese medicine composition B group of the present invention, namely the Chinese medicine composition high dose group that the embodiment of the present invention 2 is obtained significantly can reduce the hemorheology index level of rat, effect is better than positive controls, and middle dosage group and low dose group also have certain reduction effect to hemorheology index level.
To sum up, Chinese medicine composition of the present invention is remarkable to the therapeutic effect of blood stasis, can be used for the clinical treatment of cerebral thrombosis.
test two: Chinese medicine composition of the present invention is on the impact of cerebral thrombosis rat model plasma lysophosphatidic acid and phosphatidic acid level
1, test principle and object: lysophosphatidic acid (LPA) and phosphatidic acid (PA) are all the intermediate products of phospholipid metabolism.Under normal circumstances, the content of LPA in blood plasma is very low, and the platelet of human or animal by the effect release LPA of phospholipase, makes LPA level in blood plasma raise after being subject to stimulated by thrombin activation.LPA can assemble and smooth muscle contraction by stimulating platelet, promotes blood vessel endothelium hypertrophy, plays an important role in blood coagulation and thrombosis.PA is a kind of early stage releaser of cerebral ischemia, produces in the 24h of ischemia, its level increase the degree reflecting cerebral hypoxia ischemia, relevant with the excessive formation of oxygen-derived free radicals.This test proves its preventive effect to cerebral thrombosis by research Chinese medicine composition of the present invention to the impact of LPA and PA level in cerebral thrombosis rat model blood plasma.
2, the foundation of cerebral thrombosis in rats model:
By rat with after 1% pentobarbital sodium (dosage 30-40mg/kg) intraperitoneal injection of anesthesia, dorsal position is fixed on operating-table.Skin is longitudinally cut in the positive middle part of neck, and otch is about 2cm, and be separated musculi colli, right carotid of dissociating, is upwards separated external carotid artery and internal carotid artery from common carotid artery crotch.Ligation external carotid artery, be then separated internal carotid artery to basis cranii direction, at basis cranii, place isolates arteria pterygopalatina, and its root of ligation, only retain internal carotid artery and enter basis cranii trunk.Ligation common carotid artery, temporary 2 micro-arterial clamps folder that keeps at a certain distance away closes internal carotid artery, below proximal part vascular clamp, common carotid artery place eye scissors cuts an osculum, taken out in insertion the conduit of Thrombus inducer thrombin 10U and normal saline 0.01ml fixing after, remove proximal part vascular clamp, a small amount of blood inflow catheter head end, place about 10min and form a microthrombus, then another vascular clamp is removed, slowly this thrombosis and thrombin are injected internal carotid artery, extract conduit, and by the ligation of common carotid artery incision, sew up the incision, postoperative single cage is raised.
Sham operated rats operative process is the same, injects normal saline but not Thromboembolus and thrombin.
3, test grouping and dosage regimen:
Regular grade SD rat 60, body weight 280 ~ 350g, male and female half and half, are divided into 6 groups at random, often organize 10.
Model control group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Drug test group: by Chinese medicine composition obtained for the embodiment of the present invention 3, be deployed into water the suspension that concentration is 0.6g/ml, 0.4g/ml and 0.2g/ml, for subsequent use.Get 3 groups of rats, be labeled as drug test group high dose group (dosage 2.4g/kg), middle dosage group (dosage 1.6g/kg) and low dose group (dosage 0.8g/kg), high dose group concentration is the drug suspension of 0.6g/ml, middle dosage group concentration is the drug suspension of 0.4g/ml, low dose group concentration is the drug suspension of 0.2g/ml, according to dosage every day gavage 1 time, successive administration 7 days.
Positive controls: positive control drug is Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), is deployed into the suspension of 60%, gets 1 group of rat with water, by dosage gastric infusion every day 1 time of 2.4g/kg, successive administration 7 days.
Sham operated rats: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
Normal group: get 1 group of rat, isometric(al) normal saline gavage every day 1 time, continuous gavage 7 days.
4, test method:
Model control group: prohibit diet 12h after last gavage, with reference to the method for building up Modling model of above-mentioned cerebral thrombosis in rats model.Postoperative 3h, with 1% pentobarbital sodium (dosage 30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
Drug test group: the same model control group of test method.
Positive controls: the same model control group of test method.
Sham operated rats: prohibit diet 12h after last gavage, carries out sham-operation.Postoperative 3h, with 1% pentobarbital sodium (dosage 30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
Normal group: prohibit diet 12h after last gavage, with 1% pentobarbital sodium (dosage 30-40mg/kg) intraperitoneal injection of anesthesia, through abdominal aortic blood 4ml, detects the level of LPA and PA in blood plasma.
5, result of the test: as shown in table 2.
Table 2 respectively group rat plasma LPA, PA level compares
Note: compare with model control group, positive controls and drug test group
* p< 0.05,
* p< 0.01; Compare with Normal group, sham operated rats and model control group
▲ ▲ p> 0.01.
6, conclusion (of pressure testing):
Test data show, compared with Normal group, LPA and the PA level of rats in sham-operated group without significant change, and LPA and the PA water mean pole of model control group rat significantly raise (
p> 0.01).
Compare with model control group, after Chinese medicine composition of the present invention that is high, middle dosage is intervened in advance, the rising trend of rat LPA and PA level is significantly suppressed, and effect is better than positive controls.And the effect that low dose group also has certain suppression LPA, PA level to raise, effect is suitable with positive controls.
To sum up, Chinese medicine composition of the present invention has the effect suppressing LPA and PA level to raise, and has significant preventive effect for thrombosis and cerebral ischemia.
test three: the clinical trial of Chinese medicine composition of the present invention
(1) case and diagnostic criteria
1, diagnostic criteria:
With reference to the diagnostic criteria of Chinese Medical Association about cerebral thrombosis and cerebral embolism:
1) often fall ill under rest state;
2) most of nothing is obviously had a headache and is vomitted;
3) morbidity can be comparatively slow, how to be in progress gradually, or to carry out in stage, how relevant with cerebral atherosclerosis, also shows in arteritis, hematopathy etc.;
4) general morbidity Clear consciousness or slight obstacle in 1 ~ 2 day afterwards;
5) Internal Carotid System and (or) Vertebro-basilar System sings and symptoms is had;
6) Lumbar puncture CSF generally should not contain blood;
7) CT examination finds cerebral location of lesions.
Meet above diagnostic criteria patient and informed consent, be ready that experimenter all can inclusive criteria.
2, get rid of and reject case standard:
1) transient ischemic attack;
2) check that confirmation is merged atrial fibrillation caused cerebral embolism by the cerebral tumor, cerebral trauma, cerebral parasitosis, dysbolismus, rheumatic heart disease, coronary heart disease, other heart disease;
3) gestation or women breast-feeding their children, to this medicine composition allergy sufferers;
4) the severe primary diseases such as liver, kidney, hemopoietic system and hormonal system are associated with, psychotic;
5) do not meet inclusive criteria, not by regulation medication, cannot judge that curative effect or data do not affect the treatment or safety judgement person entirely.
(2) clinical trial protocol
1, physical data:
Go out by diagnosis standard screening the clinical volunteers patient that 160 examples meet diagnosis of cerebral thrombosis standard, be divided into treatment group and matched group two groups at random, often organize each 80 examples, 42 ~ 69 years old age, 56.5 years old mean age.The influence factors such as two groups of ages, state of an illness distributions, through statistical procedures, there was no significant difference, meets a point set condition.
2, trial drug and test method:
Treatment group: Chinese medicine composition fill capsule of the present invention prepared by the embodiment of the present invention 3, every capsules drug containing 0.55g, each serving with 2, every day 3 times.
Matched group: take Xueshuan xinmaining Tablet (the accurate word Z20030145 of traditional Chinese medicines, Jilin Huakang Pharmaceutical Co., Ltd), each serving with 2, every day 3 times.
Two groups was all 1 course for the treatment of with 4 weeks, evaluated curative effect after 3 courses for the treatment of, and the lipid-lowering effect of trade-off medicine by treatment Patients Before And After blood lipids index.
3, curative effect determinate standard:
Judge according to " Chinese medical disease Standardization of diagnosis and curative effect " that State Administration of Traditional Chinese Medicine formulates:
Cure: symptom and sign disappear, and substantially can live on one's own life;
Take a turn for the better: symptom and sign take a turn for the better, the action of energy cane, or basic living can be taken care of oneself;
Do not heal: symptom and sign unchanged.
4, therapeutic effect:
1) two groups of patient clinical comparitive study, as shown in table 3.
Table 3 therapeutic effect
Clinical data shows, and Chinese medicine composition of the present invention reaches 70% for the treatment cure rate of cerebral thrombosis, and total effective rate reaches 93.75%, all far above matched group, proves traditional Chinese medicine composition for treating Be very effective of the present invention.
2) two groups of patients with lipid's Indexes Comparison, as shown in table 4.
Blood lipids index before and after table 4 patient treatment
Note: compare with before treatment, * after treatment
p< 0.05; *
p< 0.01.
Clinical testing data shows, and traditional Chinese medicine composition for treating cerebral thrombosis of the present invention obviously can lower blood lipid, has the function of significant regulating lipid metabolism, and blood fat reducing ability is obviously better than matched group.
5, conclusion (of pressure testing):
This clinical trial adopts the prescription drugs Xueshuan xinmaining Tablet for the treatment of cerebral thrombosis conventional on the market at present as a control group, by comparing with the therapeutic effect of Chinese medicine composition of the present invention, highlights the curative effect of Chinese medicine composition of the present invention.Clinical testing data shows, and Chinese medicine composition of the present invention is remarkable for the therapeutic effect of cerebral thrombosis, and has obvious lipid-reducing function, and can be used as cerebral thrombosis treatment drug use, clinical generalization value is high.
Claims (6)
1. treat the Chinese medicine composition of cerebral thrombosis for one kind, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: leaf of Moringa 28-36 part, Radix Notoginseng 23-28 part, Radix Salviae Miltiorrhizae 20-25 part, Rhizoma Chuanxiong 13-18 part, Rhizoma Sparganii 13-17 part, Radix Curcumae 12-17 part, Spica Prunellae 15-20 part, Caulis Spatholobi 15-19 part, Ramulus Uncariae Cum Uncis 8-12 part, Fructus Viticis 6-14 part, Ganoderma 7-11 part, Radix Polygoni Multiflori 5-8 part, Rhizoma Arisaematis 3-7 part, Scorpio 3-9 part and Radix Glycyrrhizae 5-13 part.
2. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: leaf of Moringa 34 parts, Radix Notoginseng 26 parts, Radix Salviae Miltiorrhizae 22 parts, Rhizoma Chuanxiong 15 parts, Rhizoma Sparganii 16 parts, Radix Curcumae 15 parts, Spica Prunellae 18 parts, Caulis Spatholobi 18 parts, Ramulus Uncariae Cum Uncis 10 parts, Fructus Viticis 12 parts, Ganoderma 9 parts, Radix Polygoni Multiflori 7 parts, Rhizoma Arisaematis 5 parts, Scorpio 6 parts and 9 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: leaf of Moringa 28 parts, Radix Notoginseng 23 parts, Radix Salviae Miltiorrhizae 20 parts, Rhizoma Chuanxiong 13 parts, Rhizoma Sparganii 13 parts, Radix Curcumae 12 parts, Spica Prunellae 15 parts, Caulis Spatholobi 15 parts, Ramulus Uncariae Cum Uncis 8 parts, Fructus Viticis 6 parts, Ganoderma 7 parts, Radix Polygoni Multiflori 5 parts, Rhizoma Arisaematis 3 parts, Scorpio 3 parts and 5 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of cerebral thrombosis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the raw material of following parts by weight: leaf of Moringa 36 parts, Radix Notoginseng 28 parts, Radix Salviae Miltiorrhizae 25 parts, Rhizoma Chuanxiong 18 parts, Rhizoma Sparganii 17 parts, Radix Curcumae 17 parts, Spica Prunellae 20 parts, Caulis Spatholobi 19 parts, Ramulus Uncariae Cum Uncis 12 parts, Fructus Viticis 14 parts, Ganoderma 11 parts, Radix Polygoni Multiflori 8 parts, Rhizoma Arisaematis 7 parts, Scorpio 9 parts and 13 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment cerebral thrombosis as described in as arbitrary in claim 1-4, is characterized in that: described Chinese medicine composition is made into granule, pill, powder, tablet or capsule.
6. prepare as arbitrary in claim 1-4 as described in the method for Chinese medicine composition for the treatment of cerebral thrombosis, it is characterized in that comprising the following steps:
(1) moringa oleifera leaf extractive is prepared: get dry leaf of Moringa, 200 ~ 270 mesh sieves are crossed after pulverizing, doubly add according to the 12-15 of leaf of Moringa fine powder gross weight the alcoholic solution that concentration expressed in percentage by volume is 60%-80%, reflux, extract, 2-3 time, each return time is 2-3h, merge extractive liquid, reclaim ethanol, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, spraying dry, cross 80-100 mesh sieve, obtain moringa oleifera leaf extractive;
(2) get Radix Salviae Miltiorrhizae, Rhizoma Sparganii, Radix Curcumae, Spica Prunellae, Caulis Spatholobi, Fructus Viticis, Radix Polygoni Multiflori, Scorpio, Rhizoma Arisaematis and Radix Glycyrrhizae, pulverize, add the soak by water 3-4h of medical material gross weight 6-8 times amount, filter; Filtering residue adds the soak by water 2.5-2h of medical material gross weight 4-6 times amount, filters; Merge twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the extractum of 1.20-1.25, drying under reduced pressure, crosses 80-100 mesh sieve, obtain extractum fine powder after pulverizing;
(3) get Radix Notoginseng, Rhizoma Chuanxiong, Ramulus Uncariae Cum Uncis and Ganoderma, grinding, cross 80-100 mesh sieve, fully mix with above-mentioned moringa oleifera leaf extractive, extractum fine powder, obtain this Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510481888.XA CN104984268A (en) | 2015-08-10 | 2015-08-10 | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510481888.XA CN104984268A (en) | 2015-08-10 | 2015-08-10 | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610335799.9A Division CN105816819A (en) | 2015-08-10 | 2015-08-10 | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104984268A true CN104984268A (en) | 2015-10-21 |
Family
ID=54296247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510481888.XA Withdrawn CN104984268A (en) | 2015-08-10 | 2015-08-10 | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104984268A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496876A (en) * | 2017-09-19 | 2017-12-22 | 韦家福 | A kind of eliminating embolism and invigorating blood circulation Chinese medicine preparation and preparation method thereof |
| CN108066627A (en) * | 2018-02-02 | 2018-05-25 | 重庆跃龙生物制药有限公司 | For treating Chinese medicine composition of cerebral thrombus and/or cerebral hemorrhage and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401347A (en) * | 2001-09-07 | 2003-03-12 | 孙守贵 | Brain and heart recovery pill |
| CN101066303A (en) * | 2006-05-05 | 2007-11-07 | 文振生 | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn |
| CN101167973A (en) * | 2007-10-26 | 2008-04-30 | 马万凯 | Traditional Chinese medicine for treating hyperlipemia |
| CN104138424A (en) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | Traditional Chinese medicine composition and preparation method and pharmaceutical use thereof |
-
2015
- 2015-08-10 CN CN201510481888.XA patent/CN104984268A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401347A (en) * | 2001-09-07 | 2003-03-12 | 孙守贵 | Brain and heart recovery pill |
| CN101066303A (en) * | 2006-05-05 | 2007-11-07 | 文振生 | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn |
| CN101167973A (en) * | 2007-10-26 | 2008-04-30 | 马万凯 | Traditional Chinese medicine for treating hyperlipemia |
| CN104138424A (en) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | Traditional Chinese medicine composition and preparation method and pharmaceutical use thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496876A (en) * | 2017-09-19 | 2017-12-22 | 韦家福 | A kind of eliminating embolism and invigorating blood circulation Chinese medicine preparation and preparation method thereof |
| CN108066627A (en) * | 2018-02-02 | 2018-05-25 | 重庆跃龙生物制药有限公司 | For treating Chinese medicine composition of cerebral thrombus and/or cerebral hemorrhage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057946B (en) | Traditional Chinese medicine for treating heart disease | |
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN101804110B (en) | Traditional Chinese medicine preparation for thrombosis and blood lipid | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN102344880A (en) | Health wine and production method thereof | |
| CN104815232A (en) | Traditional Chinese medicine preparation for treating primary pulmonary hypertension and preparation method thereof | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN105816819A (en) | Method for preparing traditional Chinese medicine composition for treating cerebral thrombosis | |
| CN112057501A (en) | Traditional Chinese medicine composition, traditional Chinese medicine ointment and external hot compress plaster for treating muscular atrophy and myasthenia | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN104225363A (en) | Pharmaceutical preparation for treating cerebral thrombosis | |
| CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN104940279A (en) | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN105343449A (en) | Application of medicine combination in preparing medicine for treating cerebral thrombosis | |
| CN105055797A (en) | Traditional Chinese medicine composite for treating cerebral thrombosis and application thereof | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases | |
| CN105833181A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparing method thereof | |
| CN105194300A (en) | Pharmaceutical composition for treating cerebral thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151021 |
|
| WW01 | Invention patent application withdrawn after publication |